[Candidiasis prevention in newborn infants of diabetic mothers].
Two groups of 70 newborns each, all from diabetic mothers with and without nystatin prophylaxis, were compared, during the first three weeks of age, for incidence of mucocutaneous Candida albicans contamination (17 or 30 per cent) and for moniliasis (17 per cent in the group without prophylaxis and 71 per cent with Candida albicans contamination). Reference is made to modes of birth for comparison between pathogenesis and incidence of moniliasis and the need for prophylaxis of newborns delivered by diabetic mothers or by women with intact metabolism.
D002177:Candidiasis / Q000517:prevention & control*; D002178:Candidiasis, Chronic Mucocutaneous / Q000175:diagnosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000517:prevention & control*; D009761:Nystatin / Q000627:therapeutic use; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000150:complications*
D009761:Nystatin
Untersuchungen zur Soorprophylaxe bei Neugeborenen diabetischer Mütter.